[go: up one dir, main page]

NO995966L - 5-naftalen-1-yl-1,3-dioksan-derivater, deres fremstilling og terapeutisk anvendelse - Google Patents

5-naftalen-1-yl-1,3-dioksan-derivater, deres fremstilling og terapeutisk anvendelse

Info

Publication number
NO995966L
NO995966L NO995966A NO995966A NO995966L NO 995966 L NO995966 L NO 995966L NO 995966 A NO995966 A NO 995966A NO 995966 A NO995966 A NO 995966A NO 995966 L NO995966 L NO 995966L
Authority
NO
Norway
Prior art keywords
group
atom
optionally substituted
nitrogen atom
naphthalen
Prior art date
Application number
NO995966A
Other languages
English (en)
Norwegian (no)
Other versions
NO995966D0 (no
Inventor
Gihad Dargazanli
Patrick Lardenois
Jonathan Frost
Pascal George
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9706944A external-priority patent/FR2764287B1/fr
Priority claimed from FR9706946A external-priority patent/FR2764289B1/fr
Priority claimed from FR9706947A external-priority patent/FR2764291B1/fr
Priority claimed from FR9706945A external-priority patent/FR2764288B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO995966D0 publication Critical patent/NO995966D0/no
Publication of NO995966L publication Critical patent/NO995966L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO995966A 1997-06-05 1999-12-03 5-naftalen-1-yl-1,3-dioksan-derivater, deres fremstilling og terapeutisk anvendelse NO995966L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9706944A FR2764287B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
FR9706946A FR2764289B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706947A FR2764291B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706945A FR2764288B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
PCT/FR1998/001113 WO1998055474A1 (fr) 1997-06-05 1998-06-03 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
NO995966D0 NO995966D0 (no) 1999-12-03
NO995966L true NO995966L (no) 2000-02-04

Family

ID=27447000

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995966A NO995966L (no) 1997-06-05 1999-12-03 5-naftalen-1-yl-1,3-dioksan-derivater, deres fremstilling og terapeutisk anvendelse

Country Status (18)

Country Link
EP (1) EP0986552A1 (zh)
JP (1) JP2002502412A (zh)
KR (1) KR20010013435A (zh)
CN (1) CN1265658A (zh)
AR (1) AR012908A1 (zh)
AU (1) AU8025198A (zh)
BG (1) BG103937A (zh)
BR (1) BR9810742A (zh)
CA (1) CA2290695A1 (zh)
CO (1) CO4940480A1 (zh)
EE (1) EE9900560A (zh)
HU (1) HUP0002166A3 (zh)
IL (1) IL133242A0 (zh)
NO (1) NO995966L (zh)
PL (1) PL337234A1 (zh)
SK (1) SK166199A3 (zh)
TR (1) TR199903022T2 (zh)
WO (1) WO1998055474A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1250213C (zh) * 2000-07-21 2006-04-12 奥索-麦克尼尔药品公司 用于预防或治疗神经性疼痛和丛集性头痛及有或没有先兆的偏头痛的氨基甲酸酯化合物
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0461958T3 (da) * 1990-06-15 1995-02-20 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien
FR2714055B1 (fr) * 1993-12-22 1996-01-19 Synthelabo Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique.
FR2742152B1 (fr) * 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HUP0002166A2 (hu) 2001-06-28
BR9810742A (pt) 2000-09-12
AR012908A1 (es) 2000-11-22
IL133242A0 (en) 2001-03-19
EP0986552A1 (fr) 2000-03-22
BG103937A (en) 2000-07-31
CA2290695A1 (en) 1998-12-10
JP2002502412A (ja) 2002-01-22
HUP0002166A3 (en) 2002-12-28
CN1265658A (zh) 2000-09-06
PL337234A1 (en) 2000-08-14
CO4940480A1 (es) 2000-07-24
KR20010013435A (ko) 2001-02-26
EE9900560A (et) 2000-06-15
NO995966D0 (no) 1999-12-03
WO1998055474A1 (fr) 1998-12-10
TR199903022T2 (xx) 2000-04-21
SK166199A3 (en) 2000-06-12
AU8025198A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
HUP0303652A2 (hu) Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
NZ528851A (en) N-aroyl cyclic amines
GB9917408D0 (en) Compounds
TW200505834A (en) Sulfamide derivative and the pharmaceutical composition thereof
NO872686D0 (no) Nye farmakologiske forbindelser.
HUP0104867A2 (hu) Gyulladásos betegségek kezelésére használható heterociklusos vegyületek, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0103283A2 (hu) Proteázokat gátló pirazinonszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása
NO962543L (no) Cykliske amid-derivater som neurokinin A-antagonister
HUT74367A (en) Fungicidal alpha-aryl-substituted cyclic amide derivatives, fungicid compositions containing these as active ingredients and using thereof
MY102866A (en) Amide derivatives.
NO932005L (no) Angiotensin-II-antagonister
NO931695L (no) Nye 4-arylpiperaciner og 4-arylpiperidiner
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
FR2674855B1 (fr) Derives de piperidine, leur preparation et leur application en therapeutique.
NO996108L (no) 9-oksinerytromycinderivater
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
YU41600A (sh) 2,3-substituisana indol jedinjenja kao cox-2 inhibitori
DK0652000T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et lægemiddel til inhibering af angiogenese og angiogene sygdomme
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
HUP9701588A2 (hu) Új flavonszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
DK163581C (da) Kondenserede pyrazol-3-oxo-propannitrilderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende forbindelserne

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application